JP2004516265A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516265A5
JP2004516265A5 JP2002550973A JP2002550973A JP2004516265A5 JP 2004516265 A5 JP2004516265 A5 JP 2004516265A5 JP 2002550973 A JP2002550973 A JP 2002550973A JP 2002550973 A JP2002550973 A JP 2002550973A JP 2004516265 A5 JP2004516265 A5 JP 2004516265A5
Authority
JP
Japan
Prior art keywords
naturally occurring
pharmaceutical formulation
formulation according
sterile pharmaceutical
egg lecithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002550973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516265A (ja
Filing date
Publication date
Priority claimed from US09/745,018 external-priority patent/US6399087B1/en
Application filed filed Critical
Publication of JP2004516265A publication Critical patent/JP2004516265A/ja
Publication of JP2004516265A5 publication Critical patent/JP2004516265A5/ja
Pending legal-status Critical Current

Links

JP2002550973A 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤 Pending JP2004516265A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition
PCT/US2001/022248 WO2002049631A1 (en) 2000-12-20 2001-07-16 Propofol formulation with enhanced microbial inhibition

Publications (2)

Publication Number Publication Date
JP2004516265A JP2004516265A (ja) 2004-06-03
JP2004516265A5 true JP2004516265A5 (enExample) 2005-01-27

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002550973A Pending JP2004516265A (ja) 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤

Country Status (11)

Country Link
US (1) US6399087B1 (enExample)
EP (1) EP1250130A4 (enExample)
JP (1) JP2004516265A (enExample)
CN (1) CN1359677A (enExample)
AU (1) AU7592501A (enExample)
BR (1) BR0109769A (enExample)
CA (1) CA2397990A1 (enExample)
MX (1) MXPA02008097A (enExample)
RU (1) RU2244545C2 (enExample)
UA (1) UA73970C2 (enExample)
WO (1) WO2002049631A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040171691A1 (en) * 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
KR101910213B1 (ko) * 2011-01-04 2018-12-19 노바리크 게엠베하 부분불소화된 알칸을 포함하는 수중유형 에멀젼
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
MX348831B (es) * 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
MX369121B (es) 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
IN2014DN10322A (enExample) 2012-05-16 2015-08-07 Mewa Singh
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
TW201642843A (zh) 2015-03-27 2016-12-16 歌林達有限公司 他噴他多腸胃外給藥的穩定製劑
WO2017017693A1 (en) * 2015-07-24 2017-02-02 Neon Laboratories Limited Stabilized injectable emulsion of propofol and ketamine
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
JP4198318B2 (ja) * 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Similar Documents

Publication Publication Date Title
USD540349S1 (en) Air cylinder
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
ITTO20010005A0 (it) Formulazione farmaceutica.
MXPA03006884A (es) Formulacion farmaceutica.
JP2004210767A5 (enExample)
MXPA03007641A (es) Formulacion farmaceutica.
DE50012448D1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
MXPA03007215A (es) Formulaciones farmaceuticas.
PT1362027E (pt) 6,7,8,9-tetra-hidro-5h-benzociclo-heptenilaminas aciladas e a sua utilização como fármacos
JP2007522094A5 (enExample)
USD547455S1 (en) Baby teether
USD555241S1 (en) Straight handpiece
USD561649S1 (en) Cycle
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
JP2007520565A5 (enExample)
NO20030231D0 (no) Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter
JP2005509503A5 (enExample)
USD503883S1 (en) Packaging for a novelty gag gift
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
USD582615S1 (en) Exercise equipment for pets
USD526283S1 (en) Electrical rocker switch actuator
USD517212S1 (en) Tweezers
USD534074S1 (en) Packaging
NL1023797A1 (nl) Farmaceutische doseringsvorm die zwangerschapsvriendelijke onderscheidingstekens draagt.